Technology Transfer Office of University of Colorado
Technology Transfer Office of University of Colorado

News and Events

TTO Twitter


TTO Blog


Join Mailing List

Technology Transfer Office of University of Colorado


News and Events > Events

TTO Faculty Seminar: Patent Strategies, Technology Commercialization
& Clinical Development (a Case Study)

Tuesday, December 13, 2011, noon to 1:00pm
Lunch available at 11:45
Anschutz Medical Campus, Health Sciences Library Reading Room

This seminar will present a case study (based on a patented and licensed invention by Dr. Paul Bunn, Dr. Fred Hirsch and others representing a team of investigators in the CU Cancer Center) illustrating how research, patenting decisions, and clinical development all potentially interact.

This case study will help answer questions like:

-How do you know that your new invention is patentable?
-How can decisions made in the patenting process increase the value of your technology?
-How do commercialization decisions influence patent prosecution?
-How do patenting decisions affect commercialization?


Paul A. Bunn, Jr. is the James Dudley Chair in Cancer Research in the Division of Medical Oncology, CU School of Medicine; he previously served as Director of the CU Cancer Center. Dr. Bunn is an inventor on 20 U.S. patents and patent applications. He is a founder of ApopLogic Pharmaceuticals; other licensees of his patents include Abbott Molecular, Ventana, Syndax Pharmaceuticals, and Colorado Cancer Therapeutics.

Fred R. Hirsch is a Professor of Medicine (Division of Medical Oncology) and Pathology at the CU School of Medicine. Dr. Hirsch is an inventor on 8 patents and patent applications; licensees of his patents and technology include Abbott Molecular, Ventana, Syndax Pharmaceuticals, and Biodesix.

Robert D. Traver is a patent attorney with Sheridan Ross PC, and has been involved throughout the prosecution of this patent. His practice emphasizes all aspects of domestic and foreign patent prosecution in pharmaceuticals, chemistry, biochemistry, therapeutic methods, diagnostic methods and nutraceuticals, as wells as licensing, opinions, and due diligence reviews. Prior to joining Sheridan Ross, Rob conducted toxicological and molecular research on the role of phase II metabolism in cancer, and the efficacy of anti-cancer compounds.



This event is free and open to CU faculty from all campuses. Lunch will be provided – please RSVP via email or at 303-724-1039.


Technology Transfer Office